International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

An Overview of Mesoporous Silica Nanoparticles (MSNS) As Drug Delivery System

Sourav Pattanayak
M. Pharm, MBA (Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management)

Submitted: 15-07-2023 Accepted: 25-07-2023

ABSTRACT: Medication delivery systems could be made with mesoporous silica nanoparticles. Nanoparticles could be employed as a medical chemical transporter, according to researchers at the University of Bath and the Wales Royal Infirmary. They may be able to limit disease progression and minimise inflammatory responses, so improving cancer treatment effectiveness. Delivery strategies that improve the pharmacokinetics of loaded medications have grown in popularity in recent years. Because of their inherent structural, textural, and chemical properties, mesoporous silica nanoparticles may be employed as drug delivery platforms. Researchers are drawn to it because of its high loading capacity, increased biocompatibility, and simplicity of functionalization (DDS). In reaction to internal or external cues, nanosystems can target sick tissue and disseminate cargo. This carrier should be available shortly, according to current trends.

KEYWORDS: Nanoparticles of mesoporous silica; methods for drug administration; methods for drug loading; pharmacokinetics; toxicity; and biocompatibility.

I. INTRODUCTION :

Mesoporous silica nanoparticles (MSNs) with pore sizes ranging from 2 to 50 nm are defined by the International Union of Pure and Applied Chemistry. The Mobil Corporation created the first ordered MSNs, known as Mobil Composition of Matter or Mobil Crystalline Materials, in 1992. (MCM).[1-4] Nanoparticles outperform typical drug carriers in terms of pharmacokinetics and biodistribution, reducing toxicity while enhancing therapeutic agent concentration at the target site.[5]Mesoporous silica nanoparticles have grabbed the interest of many biomedical researchers due to their numerous benefits. Only a few of them are biocompatibility, distinctive pore size and structural properties, large surface areas and pore volumes, and excellent thermal and chemical stabilities.[6–10] They could be employed as carriers for a variety of therapeutically beneficial guest molecules in drug delivery systems (e.g.,anticancer medications[11], proteins[12],genes[13–14], antibiotics, nonsteroidal anti-inflammatory drugs, and so on).[15] Silica-based nanoparticles have received a lot of attention recently as contrast agents[16-18] and drug delivery vehicles.[19–20]Silicosis, lung cancer, and chronic obstructive pulmonary disease have all been associated to crystalline silicates. Amorphous silica nanoparticles have shown promise as an imaging and therapeutic platform.[21]Because of its inherent biodegradability and wide surface area, MSNs are emerging as promising imaging platforms. Because of their well-known medication transport and targeting capabilities, mesoporous nanoparticles are gaining prominence. Nanotechnology has changed both the pharmaceutical industry and medical delivery.[23]Nanoparticles of mesoporous silica have emerged as a feasible and distinct drug carrier for a number of therapeutic compounds.[24-25]Vallet-Reg et al. presented MCM-41 in 2001 as a medication delivery system for a variety of illnesses, with a particular emphasis on cancer treatment. Much work has been put into generating adaptive MSNs for the treatment of a wide range of illnesses, including cancer.[27-28] Furthermore, the textural features of MSNs influence how well these nanosystems operate as drug delivery mechanisms.[29-30] SBA-12, SBA-15, SBA-16,MCM-41, and MCM-48, are all mesoporous carriers with different morphologies, pore sizes, and structures.[31-32]SBA-15, MCM-41, and MCM-48 are three of the most well-known mesoporous silica materials, with pore sizes ranging from 2 to 10 nm and structural properties ranging from 2D-hexagonal to 3D-cubic.[33-34]The International Union of Pure and Applied Chemistry (IUPAC) categorises materials according to their fluid accessibility (closed, open, blind, or via pores) and form (holes that are cylindrical, ink-bottle-shaped, funnel-shaped, or slit-shaped).[35-37]

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

Nanomaterials are used as excipients in medications, cosmetics, and nutritional supplements, according to the Food and Drug Administration in the United States. Because of their structural benefits, including as large pore size and surface area, MSNs are a versatile substrate that can be used for a variety of biological applications, including diagnostic imaging.[38] biosensing,[39] biocatalysis,[40-42]drug administration,[43-45] as well as bone restoration and scaffold engineering,[46-48] Caruso and colleagues created submicron-sized polymer capsules for cancer medication delivery by using mesoporoussilica particles as templates.[49-50] The most recent study on mesoporous silica particles as drug transporters is presented in "Drug formulation." Loading processes and physicochemical methods for assessing the molecular state of the drug will be discussed.For the first time, the European Medicines Agency (EMA) issued an assessment of MSN and other pharmaceuticals used in DDS production procedures, drug loading techniques, alterations, pharmacokinetics, pharmacology, biocompatibility, and toxicity.[51]

II. SYNTHESIS OF MSNS

MSNs are molecules formed by hydrolyzing, condensing, or dissolving silanes in acidic, neutral, or basic aqueous solutions.[52] As structure-directing agents, non-ionic (cationic or non-ionic surfactant) or amphiphilic block copolymers are used and are essential in the synthesis of organic molecules such as paint, plastics, paints, and detergents.[53]The specific method through which MSNs emerge has been questioned. To characterise the MSN production mechanism, a "current bun model" was proposed. Time-resolved small-angle neutron scattering was used to confirm the "current bun model", which involved Hydrolyzed silicon sources were either electrically arranged onto cationic micelles or silica polymers were synthesised before attaching to non-ionic micelles. Micelles condensed into larger particles as a result of silica condensation. [54-55]Understanding and predicting MSN formation necessitates the finding of interactions between silica precursors and micelles during hydrolysis and condensation. A novel "swelling-shrinking" approach has been developed to discover the origins of MSNs. MSN synthesis with TEOS as a silicon source and CTAB as a structure-directing agent aided the "swelling-shrinking" mechanism. To begin, CTAB was dissolved in a buffer solution (pH 7.2). When TEOS was added to CTAB hydrocarbon cores, it was solubilized, resulting in micelle enlargement. The micelles shrivelled and shrunk when all of the TEOS in the CTAB hydrocarbon cores was eaten.[56-58]One-pot synthesis and microwave-assisted synthesis are two of the novel techniques that have been demonstrated.[59-60]

III. MSN CLASSIFICATION USED FOR DRUG DELIVERY

In recent years, drug delivery systems such as SBA systems, MCM systems, TUD systems, and KIT systems have been developed. MSNs with various morphologies and structures can be produced utilising various structure-directing agents.[61-64]



MSNs	FULL NAME
MSU	Michigan State University
SBA	Santa Barbara Amorphous
MCM	Mobil Crystalline Matter / Mobil Composite Matter
HMS	Hollow Mesoporous Silica
OMS	Ordered Mesoporous Silica
TUD	Technische Universteit Delft
MCF	Meso Cellular Form
FSM	Folded Sheet Mesoporous
KIT	Korean Advanced Institute of Technology
FDU	Fairleigh Dickinson University

FIG 01: Various Mesoporous materials utilised as drug delivery systems are depicted in a schematic diagram.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

3.1Traditional MSNs

The MCM system, a two-dimensional hexagonal structure with a huge surface area, and a narrow pore size distribution and high thermal stability, has found widespread application in biomedicine. MCM-41 has successfully delivered vancomycin, IBU, aspirin, and hypocrellin A. These are the primary components of the MCM system.[65-68]The surface area of MCM-48 is 1.3 times that of MCM-41, and the pores are regular cubic bicontinuous. Surfactant molecules have a one-dimensional stratiform shape due to sheets or bilayers with hydrophilic head groups oriented toward the silicate at the interface.[69] In drug distribution, a medicine having a hexagonal mesoporous structure was used. Pore walls with thinner walls (3.1–6.4 nm), bigger pore sizes (5–30 nm), The SBA-15 is distinguished by a finer surface morphology.[70-71]zKIT-6 with pH-responsive Curcumin (CUR)-loaded guanidine functionalized polyethylene glycolylated (PEGylated) controlled characteristics and highly programmed release was discovered to be particularly beneficial in treatment of breast cancer.[72]

3.2Hollow MSN

Hollow mesoporous drug carriers (HMSNs) have a hollow core. the mesoporous shell functions as a conduit for chemical encapsulation, while The hollow core functions as a reservoir or microreactor or as a large surface area for diverse reactions.[73] Further research found that IBU in HMSNs had a higher loading capacity than MCM-48 and MCM-41.[74]HMSNs exhibit shell fragility when the template is removed due to their flimsy shell, which might as a result of medication loading or tableting, the mesopore wall collapses, lowering the therapeutic efficacy of the medication.[75]

3.3MSNs with lipid bilayer coating

Phosphatidylcholine-structured liposomes spontaneously fuse to the surface of lipid bilayer-coated MSNs (LB-MSNs), also known as protocells.[76] The lipid bilayer preserves biomolecules by limiting or reducing nonspecific adsorption and protein denaturation.[77]Furthermore, the lipid bilayer of MSNs can operate as a drug diffusional barrier, preventing undesirable drug leakage. MSNs have a huge surface area and can transport large payloads while also providing solid support for a more stable lipid bilayer.[78-79]MCF-7 cells absorb LB-MSNs more readily after lipid coating, and their biocompatibility improves. MSNs were coated with a lipid layer (hypocrellin B, HB) containing drugs, short interfering RNA, and toxins. After light irradiation, HB was more hazardous than HB-loaded MSNs.[80]Recently, GEM/PTX were co-delivered to Mice with human pancreatic cancer at a 10:1 ratio via LB-MSNs, GEM was found in the MSNs, and PTX was found in the lipid bilayer.[81]Co-delivery of PTX and GEM using LB-MSNs reduced pancreatic cancer stromal volume and tumour growth, exceeding free GEM with Abraxane. Hepatocellular carcinoma in humans showed a 10,000-fold increase in attraction for hepatocytes, endothelial cells, and immune cells.[82-84]

3.4 Modified MSNs

Drug adsorption and release control, as well as personalised medicinal delivery, are made possible by modifying MSNs. polymers, targeting moieties and Organic functional groups, can be used to replace surface silanol groups on MSNs. Organic molecules, such as silanes, can be synthesisedby covalently connecting functional groups through co-condensation.[85]Co-condensation has been demonstrated to be preferable for the interior surface of the mesopores due to its ease of use, consistency in functionalization distribution, and high drug loading. Due to its ease of use, consistency in functionalization distribution, and For the interior surface of mesopores with high drug loading, co-condensation has been stated to be preferable. The most striking characteristic of the post-synthetic grafting process is its capacity to selectively functionalize the exterior or interior surfaces of MSNs. The surface can still be selectively functionalized if the grafting surfactant is still present. In biomedical applications, MSN modification can be utilised to modify the surface charge and chemically Interact with functional molecules either within or outside of pores.[86]

IV. DRUG LOADING PROCESS

Melt procedures, supercritical fluid technologies, and organic solvent loading techniques have all advanced in the recent decade. The drug loading approach is built around drug adsorption on the surface of mesoporous silica.[87-88]A perfect medicine loading technique would be capable of rapidly loading a big quantity of the medicine, followed by emptying it with the specified release profile and minimal waste.[89-91]

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

4.1Meltingprocess

The melt technique includes heating the drug-loaded mesoporous system exceeding the drug's melting point, which may lead to drug degradation.[92]A melt method was used to load IBU into MCM-41. When utilising this method, it is vital to consider the drug's melt viscosity and temperature stability.[93]IBU was mixed with MSNs and heated to 5°C above the melting point of IBU. ITR was combined with SBA-15 and heated to temperatures exceeding the melting point of ITR. This is an excellent method of containing Medicine is injected into the pores at a filling ratio of 60%.(medicationloading through the pores).[94]

4.2The solvent immersion process

Several research groups have published extensively on organic solvent drug loading techniques in the literature. The most common approach involves adsorption from an organic solution and filtering to remove the drug-loaded mesoporous silica.[95-97]Adsorption is usually a low-yield approach since it is restricted to a monolayer on the surface.[98] Furthermore, according to ICH guideline Q3 (International Conference on Harmonisation), the solvent must be reduced to acceptable levels (R5).[99] Polar solvents such as dimethylformamide (DMF), and dimethylacetamide (DMA) dimethyl sulfoxide (DMSO) resulted in limited ibuprofen loading onto MCM-41.Interactions between the medication, silica, and the solvent can have an impact on drug loading.[100] In ethanol and hexane, drug loading concentrations were relatively high (nonpolar solvents). If the concentration of the drug is too high, it will easily adsorb on the surface and clog the mesopores. The correct drug concentration in solvent must be estimated prior to drug loading.[101]

4.3The process of impregnation by wetness

Creating a concentrated drug solution in solvent, adding it to MSNs drop by drop, as well as drying the drug-laced powder are all steps in a single-step incipient wetness impregnation technique. When the solvent is withdrawn, the concentrated drug mixture is taken up by capillary forces and retained within the pores.[102-103] Fenofibrate was injected into MSNs through solvent impregnation. Preliminary wetness impregnation Long-term drug soaking is required and has a significantly lower filling factor, is less efficient than melt impregnation. The similar procedure was used to import IBU into MCM-41.[104]

4.4 Loading using supercritical fluid technology

SCF is a technique for loading medicines into mesoporous silicas, which find application in the chromatography industries and food[105-107]They can be utilised as impregnating agents because to their peculiar features, which include gas-like viscosity, liquid-like density, low interfacial tension and higher diffusivity than liquids.[108]SCF drug loading approaches provide various advantages by utilising the solvent power fluctuation caused by altering the supercritical fluid pressure and temperature, CO2 is the most commonly used SCF fluid because of its low critical point (7.4 MPa, 31.2°C). In supercritical CO2 settings, many medications have been shown to disintegrate.[109-111]SCF generates no residual solvent when conducted without the use of a cosolvent. Many medicines, including FEN, clotrimazole, glyburide, and asarone have demonstrated SCCO2 solubility.[112-113]Another advantage of SCF for drug loading is that after fluid evacuation, the final product is solvent-free. The SCF method has been directly compared to the solvent method in studies.[114] The SCF technology offers an alternate, environmentally friendly means of loading drugs onto silica support, as well as a two-hour processing time. The yield, lifespan, and physical features of the drug were compared for each impregnation process. Stam and colleagues discovered that a low concentration of ibuprofen in nonpolar liquid CO2 was sufficient to induce maximum drug loading in MCM-41 pores.[115]According to these findings, liquid CO2, which is less expensive than SCCO2, can be a viable "green solvent" for medication incorporation into mesoporous silica. Ahern and colleagues investigated the use of supercritical and liquid CO2 technologies in the mixing, melting, and solvent evaporation processes.[116-117] A novel sol-gel synthesis technique for loading pharmaceuticals into MSNs has also been revealed, employing drug micelles as a template.[118-119]Measuring the success of drug loading in MSNs using direct and indirect strategies. The supernatant can then be collected and analysed using high-performance liquid chromatography or UV spectroscopy after drug loading. By subtracting the drug added from the drug unloaded, the amount of drug loaded is calculated using indirect measurement methods.[120-121]HPLC can, however, be used to determine the amount of medication put into MSNs powder. Aminosilanes can be used to functionalize negatively charged MSNs on the silica surface. The

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

drug's molecular size should be determined using density functional theory prior to loading (DFT).[122-123]As a result, various features of compressed carbon dioxide have been noted as potential benefits of this method, such as its ability to lower the melting point of the compound and make the molten products less viscous.[124]

4.5 Large-scale loadingtechniques

Prior laboratory procedures for pharmaceutical loading are adequate for small batch sizes. Limnell et al. investigated rotavapor, immersion, and fluid-bed loading.[125]They stated that these methods reduce the need for large doses of drugs, making them less expensive. Researchers at the University of Bristol have also looked into a co-spray drying technique. Furthermore, they asserted that in the immersion approach, which is more cost-effective, these procedures reduce the need for large doses of drugs. During testing, they discovered that the amorphous drug had a high level of drug loading and physical stability.[126-127]Indomethacin was co-milled onto a silica substrate by Bahl et al. using a rolling jar mill. The material remained physically stable for 3–6 months at 40°C and 75% relative humidity (RH).[128]

V. THE PROPERTIES OF MESOPOROUS SILICA IN REGULATING DRUG RELEASE AND LOADING

5.1 Silica particle properties and pore structure

The most important factors are pore volume, pore size, and surface area. Particle characteristics (such as particle shape and size) also have an effect. By loading ibuprofen onto various mesoporous silicas, Heikkilä et al. investigated the effect of pore volume on drug adsorption.[129]The total volume of mesopores has a major impact on drug loading. Excessive drug loading can result in the formation of a crystalline drug coating on the silica surface, which limits drug release. The total pore volume and pore size, according to Zhang et al., limit maximal drug loading.[130-135]

Fig: Different groups of analytical techniques used for MSNs characterization



Several organisations have observed that Amorphous drugs can be kept for a long time in mesopores. The drug molecule will not recrystallize if the confinement space width is less than or equal to 15 times the diameter of the drug molecule.[136-137]The rate of release slows as

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

molecules congregate closer together in mesopores. The amount of drug loaded decreases with decreasing pore size. All aspects of drug loading and release, as well as pore size, have been investigated.[138] Ibuprofen molecules released through the same sized holes were compared to the pore size of erythromycin molecules. To allow for simple drug loading and release, the pore size should be at least three times larger than the diameter of the drug molecule.[139-140]During the manufacturing process, the pore sizes of ordered mesoporous silicas such as MCM-41 and SBA-15 can be changed. As a result, the rate at which medication is released can be regulated.[141-142] Certain chemicals, however, have a hole size threshold at which increasing pore width does not improve release rate.[143]Furthermore, greater recrystallization has been linked to a reduction in Larger pore diameters in silica samples enable nano-containment capabilities.[144-147]In vitro, a larger pore diameter resulted in faster release, whereas in vivo, a smaller hole diameter resulted in the fastest release profile. The slower rate of supersaturation in the colon, according to the researchers, is related to the smaller pore diameter, which improves fenofibrate absorption across the intestinal wall.[148-150]Particle size and shape have been studied in terms of drug loading and release. It is possible to create mesoporous silica particles with a monodisperse particle size.[151-152]The literature has paid little attention to the utility of reducing silica particle size further to improve drug loading and release. The importance of particle morphology has been investigated, however the results have been mixed.[153-155] Mesoporous silica is an excellent carrier for drugs that are not water soluble due to its huge surface area.[156] A higher surface area increases pharmacological loading and breakdown, according to several research.[157] According to a recent study, Increases in surface area do not always result in a linear increase in drug release rate.[158]

5.2Surface functionalization

Silica surface functionalization opens up new avenues for drug adsorption and release management.The goal of functionalization is to increase the drug's silica affinity.For functionalizing co-condensation, grafting, mesoporous silica and the impression coating method are all viable methods.[159-160] Numerous medications have been integrated into various functionalized systems in this fast evolving business. Balas et al. investigated the loading of alendronate in amino-functionalized and nonfunctionalized silica. According to a solvent loading approach, the drug loading for the modified silica material was around three times higher.[161]To develop a controlled-release erythromycin formulation, SBA-15 was functionalized with octyl and octadecyl groups. Aqueous media have a hard time penetrating the functionalized silica structure. Binding hydrophobic species to the surface is the second strategy for surface functionalization.[162]Using aqueous solutions, the functional groups reduced the SBA-15's effective pore size and wettability, resulting in a controlled-release formulation. Captopril and ibuprofen were used as model medicines, and silylated mesoporous silica was used to create controlled-release formulations. These technologies hold promise for regulated and targeted medicine delivery in the future.[163]

VI. MSNS PHARMACOKINETICS

MSNs are a promising biomaterial, but their interaction with the body is unknown. MSN absorption, distribution, and excretion have been characterized.The primary modalities for MSN biomedical application are intravenous (IV) or oral administration.

6.1MSN Absorption and distribution in vivo

MSN absorbs and disperses depending on the delivery technique, as opposed to IV medicine, which absorbs through the gastrointestinal tract. MSNs in the liver were identified using TEM and inductively coupled plasma-optical emission spectrometry after MSNs were administered orally. MSN levels rose during the first seven days after an oral dose, then fell as a result of IV treatment. During IV therapy, MSNs primarily accumulated in the liver and spleen.[164-166]In contrast to IV medicine, which absorbs through the gastrointestinal tract, MSN absorbs and disperses depending on the delivery strategy. MSNs were discovered in the liver after MSN administration orally. During the first seven days after oral delivery, the amount of MSN grew, then dropped.[167-168] MSN increased during the first seven days following oral dose, then reduced as a result of IV treatment. MSNs largely gathered in the liver and spleen during IV therapy.[169]

6.2 MSN excretion in vivo

It is crucial to consider how nanoparticles will be removed from the body before using them in biomedicine. MSNs are primarily removed by

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

urine and faeces after delivery. Following injection, 95 percent of the Si was excreted in urine and faeces, suggesting that MSNs can be entirely eliminated by the body.[170] Furthermore, 24 hours after oral delivery, the majority of MSNs were discovered in the faeces. Following IV treatment, intact MSNs were detected in the urine. No undamaged MSNs were found in the urine after 24 hours. MSN metabolism and physicochemical properties alter in different physiological situations, which could explain the difference.[171] MSNs enter the bloodstream and go to nearly every organ, including the liver and spleen. However, the pharmacokinetic features of many drugs can vary depending on how they are administered. Porosity, shape and size, surface functionalization, and surface oxidation are all factors to consider.[172]

VII. MSN TOXICITY AND BIOCOMPATIBILITY

Because MSNs are inorganic nanoparticles that are difficult to dissolve in the body, it is critical to understand their toxicity and biocompatibility before using them in a therapeutic setting.

7.1 Genotoxicity

MSN cytotoxicity has gotten a lot of attention, whereas MSN genotoxicity has gotten less.[173-176]After being exposed to MSNs with average sizes of 25 and 100 nm for 24 hours, HT-29 cells exhibited a mild genotoxic effect.[177-178] More research is needed to figure out how Genot toxicity is affected by MSN surface chemistry, shape and coating with other novel materials. However, even MSNs with high biocompatibility can cause genotoxicity. According to microarray studies, 579 genes were elevated when MSNs were administered at a dosage of 120 g/mL for 24 hours. According to the study, while employing MSNs with high drug loading, treatment duration and focus must be excessive.[179-180]

7.2Biocompatibility and cytotoxicity of cells

MSNs have shown to easily integrate into the majority of normal and malignant cells, with no discernible effects on cell growth, proliferation, or differentiation. MSNs can only be employed in clinical settings if they are not harmful to people.[181] In an MTT assay, MSNs with wavelengths spanning from 30 to 300 nm were found to be non-toxic to HeLa cells. Smaller MSNs absorb more light and have more silanol groups available for cell contact, making larger MSNs excellent for medical applications.[182] Despite the fact that low-dose MSNs have minimal cytotoxicity (50 g/mL), high-dose MSNs have significant cytotoxicity (> 200 g/mL). In vitro cytotoxicity tests with 800g/mL MSNs revealed nephrotoxicity. Furthermore, hazardous surfactants such as CTAB that are remaining in the pores following MSN production have been shown to be cytotoxic. As a result, toxic surfactants must be completely eliminated from MSN pores prior to drug loading via extraction or calcination.[183]

7.3Biocompatibility of blood

When employing drug-loaded carriers for vein injection, blood biocompatibility is critical. Thrombogenicity, hemolytic activity, and blood protein adsorption should all be assessed prior to IV treatment. Surface functionalization, according to studies, reduces the activity of naked MSNs.[184] MSN surface modification may aid in blood biocompromat. There was no thrombogenic activity in any of the MSNs. The activated partial thromboplastin time and prothrombin time were measured. No protein adsorption was observed on MSNs ionic-functionalized surfaces after exposure to gamma globulins and serum albumin.[185]

7.4Tissue biocompatibility

For two months, mice were given 1 mg/mouse/d FMSNs twice a week, and no histological abnormalities or lesions were found. The long-term toxicity of fluorescent MSNs (FMSNs) or a saline solution was evaluated. mice were given FMSNs or a saline solution. In the spleen, liver, heart, kidney, colon, muscle, or lungs, There were no obvious histological lesions, pathological abnormalities, or gross.[186-187]Histological examination of the kidney tissues revealed tissue degradation, hyperplasia, fibrosis and necrosis. New MSN generations are being used to lessen potential toxicity. Variants in physicochemical parameters, particle shape, size, charge, surface chemistry ranges have not been investigated. Mice's kidneys showed localised bleeding and glomerulus atrophy after receiving MSNs via IV injection.[188-189]

VIII. MSNS IN DRUG DELIVERY SYSTEM

The US Department of Health and Human Services, as well as the US National Institute on Drug Abuse, state that, MSNs have the potential to be effective drug carriers, having been used to increase the solubility of a variety of pharmaceuticals (NIDAA).

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

8.1Drug solubility enhancement

Because of their high pore capacity and surface area, MSNs are used. Due to their low solubility, MSNs have been employed to administer hydrophobic medicines. Amorphous medications are more soluble than crystalline drugs because they have lower lattice energies.[190]MSNs enhanced MCM-48 saturation solubility by 95%. Res was bound in narrow, amorphous mesochannels compared to pure RES.[191]When compared to the marketed product, tmax was 0.75 hours shorter, Cmax was 77 percent higher, and AUC0-24h was 54 percent higher.[192]

8.2MSNs used as a carrier for targeted/controlled delivery

MSNs are designed to control the release of drugs and deliver specific chemicals to specific tissues or cells.

8.2.1Used as a controlled delivery vehicle.

PTX was loaded using three different MSNs (3–10 nm). Different MSNs with different pore diameters produced variable amounts of PTX. Light, magnetism, temperature, redox, pH, and other factors can all be controlled by MSNs.[193]In the pore outlet, a cyclobutane dimer is formed of thymine-functionalized MSNs after 365 nm UV irradiation. When the attached molecules were photocleaved with UV light at 240 nm, they were released. A fascinating external stimulus-triggered controlled pharmaceutical delivery technology is light-responsive controlled administration.[194-198] In addition to UV irradiation, vis-induced controlled MSN release has been established. SR101 was loaded into Ru (bpy) 2(PPh3)-moieties using mercaptopropyl-functionalized MSNs. After being exposed to Vis radiation, the capping moieties as well as the cargo Sr101 were liberated.[199] Near-infrared (NIR) two-photon stimulation has lower scattering loss, penetrates deeper into tissues, and provides three-dimensional spatial resolution.MSNs are created by fusing azobenzene moieties A, a fluorophore, and two fractophoresF.[200] MSNs could be used to treat cancer using both low and high-intensity NIR laser irradiation. MSNs can be utilised in conjunction with other photothermal treatment materials, such as gold nanorods. Because of their high drug loading and huge specific surface area, MSNs can be employed in conjunction with other photothermal treatment materials such as gold nanorods (Au@SiO2).[201] The back-and-forth movement of azo molecules in conjunction with a mesoporous silicon matrix created a molecular impeller, which allowed the drug to be delivered. As an external stimulation, magnetic fields have been used to help with the release of medications. They are non-toxic and have a high capacity to infiltrate living things without causing harm.[202] When a magnetic field is applied to double-stranded DNA, it can melt. A biodegradable silica-iron oxide hybrid nanovector is used to transport large proteins to cancer cells. Fluorescein was released by magnetic mesoporous silica particles, allowing a DDS to be activated remotely. The DDS's magnetic field increased temperature and fluid flow.[203] The unique zinc-doped iron oxide nanocrystals (ZnNCs) increased hyperthermic effects fourfold and magnetic resonance imaging (MRI) contrast tenfold.[204]Tumor tissue has higher temperatures than healthy tissue. As gatekeepers, phase-change polymers are used with higher melting points could be a viable strategy for controlling distribution.[205] MSNs were created by mixing rhodamine B and a zwitterionic sulfobetaine copolymer in order to supply GSH 100–1000 times higher than in external fluids. MSNs can also be used to deliver redox-controlled GSH, which can be 100 times more effective than exogenous fluids.[206-208] In extracellular fluids, disulfide bonds are typically very stableand are more reactive in cancer cells that have higher GSH levels.In a high GSH environment, chitosan derivatized with disulfide linkages that dissociated and broke when in touch with GSH may prevent DOX release.[209]Lactobionic acid (LA) was grafted onto collagen-capped MSNs to create the LA-Col-linker-MSN cell-targeting moiety. Furthermore, redox-responsive DDS and cell-specific targeting (CSNT) were developed.[210] When GSH became scarce, the hybrid DDS began to emerge. Higher GSH concentrations caused MSNs to release drugs more quickly. Another study used TF as a gatekeeper as well as a DDS targeting agent that can be used for both controlled and targeted DDS. To summarise, New insights into the design of MSNs were obtained by combining diverse competencies into a single moiety.[211-215] To stimulate the release of antineoplastics from MSNs, supramolecular nanovalves, polyelectrolytes, pH-sensitive linkers, and acid-decomposable inorganic compounds were used. pH-responsive MSNs can be used in cancer therapy as controlled DDS because of the pH gradients.[216] The DDS's pH-sensitive -cyclodextrin (-CD) cap and pH-sensitive N-methylbenzimidazole (MBI) stalk were sensitive to endosomal acidification.At pH 7.4, the P pH-

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

sensitive -cyclodextrin (-CD) cap and N-methylbenzimidazole MBI stalk capture drug molecules. BSA nanogates shut pores, allowing two anticancer medications to be released in response to pH with less than 3% drug leakage.[217] PDA-modified MSNS were formed on the surface of MSNs modified with polydopamine (PDA). The FA functions as a ligand, and pH-sensitive PDA coating works as a gatekeeper. It is possible to combine drug targeting and pH-controlled release.[218] When certain enzymes are overexpressed in specific organs, they can function as controlled DDS. IBU is created by grafting MSN surfaces with bridged silsesquioxane-grafted MSNs.[219-221] To increase medicine release in low pH and GSH conditions, drug delivery methods have been created. To achieve triggered release of DDS in this environment, dual drug-loaded MSNs containing hyaluronic acid and PAMAM dendrimer were designed.[222] The magnetic MSNs were copolymer-coated (MMSNs@P) to coat magnetic MSNs (NIPAM). The saturation magnetization of the MSNs in an alternating magnetic field were measured to be 6.2 emu/g As a result, heat is generated quickly.[223] When cancer cells are exposed to light in anCeO2 NPs are formed in a low pH intracellular environment with a high GSH content. According to experts at Boston's Massachusetts General Hospital (MGH), HP creates 1O2as part of photodynamic therap.[224]

8.2.2 As a vehicle for targeted delivery

When MSNs clump together in cancer cells or tissues, they form nanometer-sized clumps. Passive targeting can result in medication efflux and resistance due to a lack of cell-specific binding. MSNs have been developed to actively target medication delivery by adding targeting moieties such as mannose, HA, and lactose.[225-226] MSNs' active targeting moieties were altered, which, when paired with the EPR effect, increased MSN cellular uptake by certain tumour cells. According to the researchers, FA has the potential to be a cancer therapeutic target moiety.[227]Endothelial cell targeting, often known as vascular targeting, is a promising treatment option for solid tumours. The researchers created MSNs with a strong affinity for CD44-expressing HCT-116 cells using HA-modified MSNs. Tumor necrosis occurs when the feeding systems of quickly proliferating cancer cells are disturbed.[228-229] Anti-angiogenesis therapy may be ineffective in the battle against cancer on its own. Using it with chemotherapeutics is a good concept. For drug delivery, DOX and CA4 peptides were loaded into MSNs modified with iRGD peptides (DOX/CA4 loaded IRGD-MSNs).[230]Small molecules are transported by subcellular organelles such as the nucleus and mitochondria. Nuclear pore complexes can pass small molecules ranging in size from 20 to 70 nm (NPCs),Intranuclear transfers require nuclear localization signals (NLS).[231]The University of Bristol in the United Kingdom has created a unique nanoparticle for cervical cancer therapy. The nanoparticles' The complex DDS's high-surface-area nanoporous core allowed for significant drug loading while PDA served as a gatekeeper to restrict leakage.[232-233] Following an IV infusion of the targeting ligand RGD, magnetic MSNs clump together at the tumour site. EPR is caused by both the magnetic and active targeting effects.[234]

8.2.3As a vehicle for theranostics

MRI has made use of MSNs including inorganic nanoparticles such as manganese oxide. MSNs were loaded with QDs, organic dyes, CT contrast agentsb and MRI contrast agents.[235-236]Fe@MSNs are MRI scanners that are capable of detecting tumours in acidic conditions. FeOOH-loaded MSNs perform well in T1 MRI. One such device is a pH-responsive theranostic nanoplatform.[237] Some theranostic nanoplatforms are capable of performing precise diagnostics as well as personalised treatment regimens. MSN surfaces are linked to lanthanide-doped upconverting nanoparticles that are ultra-small, which are then impregnated with the anticancer drug DOX. This is a one-of-a-kind multipurpose MSN that can provide precise diagnostics as well as individualised treatment regimens.[238]To aid in the early identification of melanoma, fluorescent CT has been created. Magnetic core-MSNs labelled with technetium 99m have been created for single photon emission CT.[239-240]

IX. CONCLUSION AND FUTURE PERSPECTIVE

One of the most important areas of research in future pharmaceutics is nano-enabled drug delivery systems. MSNP-based multifunctional nanocarriers may be used to carry therapeutic compounds to ill Prior to releasing cells, organs, and/or organelles in response to internal or external stimuli. Melt operations, solvent immersion processes, SCF technologies, and other novel approaches have been used to convert pharmaceutical compounds into MSNs. MSNP design and manufacturing for nanomedicine

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 4 July-Aug 2023, pp: 1056-1078 www.ijprajournal.com ISSN: 2249-7781

applications has advanced. A flexible method was used to selectively functionalize MSNs. They've perfected a technique for diagnostic, imaging agents, drug delivery and cancer treatment target drug delivery. One of the most important aspects of the design of a medicine delivery platform is the loading technique MSNs have the potential to be loaded or functionalized with a wide range of molecules in order to create multifunctional stimuli-responsive drug delivery platforms. According to researchers at the Massachusetts Institute of Technology, "we believe that the enormous potential of MSNs will be realised soon."

REFERENCES :

[1]. Li Z, Zhang Y, Feng N. Mesoporous silica nanoparticles: Synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery. Expert opinion on drug delivery. 2019 Mar 4;16(3):219-37.

[2]. Kresge AC, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. nature. 1992 Oct;359(6397):710-2.

[3]. Beck JS, Vartuli JC, Roth WJ, Leonowicz ME, Kresge CT, Schmitt KD, Chu CT, Olson DH, Sheppard EW, McCullen SB, Higgins JB. A new family of mesoporous molecular sieves prepared with liquid crystal templates. Journal of the American Chemical Society. 1992 Dec 1;114(27):10834-43.

[4]. Trewyn BG, Slowing II, Giri S, Chen HT, Lin VS. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol–gel process and applications in controlled release. Accounts of chemical research. 2007 Sep 18;40(9):846-53.

[5]. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. InUrologic Oncology: Seminars and Original Investigations 2008 Jan 1 (Vol. 26, No. 1, pp. 74-85). Elsevier.

[6]. Vallet-Regi M, Rámila A, Del Real RP, Pérez-Pariente J. A new property of MCM-41: drug delivery system. Chemistry of Materials. 2001 Feb 19;13(2):308-11.

[7]. Qu F, Zhu G, Huang S, Li S, Qiu S. Effective controlled release of captopril by silylation of mesoporous MCM-41. Chemphyschem: a European journal of chemical physics and physical chemistry. 2006 Feb 13;7(2):400-6.

[8]. Yang Y, Jia Y, Gao L, Fei J, Dai L, Zhao J, Li J. Fabrication of autofluorescent protein coated mesoporous silica nanoparticles for biological application. Chemical Communications. 2011;47(44):12167-9.

[9]. Wu KC, Yamauchi Y. Controlling physical features of mesoporous silica nanoparticles (MSNs) for emerging applications. Journal of Materials Chemistry. 2012;22(4):1251-6.

[10]. Urata C, Yamada H, Wakabayashi R, Aoyama Y, Hirosawa S, Arai S, Takeoka S, Yamauchi Y, Kuroda K. Aqueous colloidal mesoporous nanoparticles with ethenylene-bridged silsesquioxane frameworks. Journal of the American Chemical Society. 2011 Jun 1;133(21):8102-5.

[11]. Slowing II, Trewyn BG, Lin VS. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. Journal of the American Chemical Society. 2007 Jul 18;129(28):8845-9.

[12]. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. small. 2007 Aug 3;3(8):1341-6.

[13]. Radu DR, Lai CY, Jeftinija K, Rowe EW, Jeftinija S, Lin VS. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. Journal of the American Chemical Society. 2004 Oct 20;126(41):13216-7.

[14]. Torney F, Trewyn BG, Lin VS, Wang K. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nature nanotechnology. 2007 May;2(5):295-300.

[15]. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. AngewandteChemie International Edition. 2007 Oct 8;46(40):7548-58.

[16]. Cormode DP, Naha PC, Fayad ZA. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast media & molecular imaging. 2014 Jan;9(1):37-52.

[17]. Wartenberg N, Fries P, Raccurt O, Guillermo A, Imbert D, Mazzanti M. A gadolinium complex confined in silica nanoparticles as a highly efficient T1/T2 MRI contrast agent. Chemistry–A European Journal. 2013 May 27;19(22):6980-3.

[18]. Milgroom A, Intrator M, Madhavan K, Mazzaro L, Shandas R, Liu B, Park D. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids and Surfaces B: Biointerfaces. 2014 Apr 1;116:652-7.

[19]. Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS nano. 2015 Apr 28;9(4):3540-57.

[20]. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. Journal of Materials Chemistry. 2011;21(16):5845-55.

[21]. Hnizdo E, Vallyathan V. Chronic obstructive pulmonary disease due to occupational exposure to silica dust: a review of epidemiological and pathological evidence. Occupational and environmental medicine. 2003 Apr 1;60(4):237-43.

[22]. Vallet-Regí M, Balas F, Arcos D. MesoporöseMaterialien für den Wirkstofftransport. AngewandteChemie. 2007 Oct 8;119(40):7692-703.

[23]. Swami A, Shi J, Gadde S, Votruba AR, Kolishetti N, Farokhzad OC. Nanoparticles for targeted and temporally controlled drug delivery. InMultifunctional nanoparticles for drug delivery applications 2012 (pp. 9-29). Springer, Boston, MA.

[24]. Kwon S, Singh RK, Perez RA, Abou Neel EA, Kim HW, Chrzanowski W. Silica-based mesoporous nanoparticles for controlled drug delivery. Journal of tissue engineering. 2013 Sep 2;4:2041731413503357.

[25]. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. International journal of pharmaceutics. 1995 Mar 14;116(1):1-9.

[26]. Vallet-Regi M, Rámila A, Del Real RP, Pérez-Pariente J. A new property of MCM-41: drug delivery system. Chemistry of Materials. 2001 Feb 19;13(2):308-11.

[27]. Butler KS, Durfee PN, Theron C, Ashley CE, Carnes EC, Brinker CJ. Protocells: modular mesoporous silica nanoparticle-supported lipid bilayers for drug delivery. small. 2016 Apr;12(16):2173-85.

[28]. Lin YS, Hurley KR, Haynes CL. Critical considerations in the biomedical use of mesoporous silica nanoparticles. The journal of physical chemistry letters. 2012 Feb 2;3(3):364-74.

[29]. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. AngewandteChemie International Edition. 2007 Oct 8;46(40):7548-58.

[30]. Vallet-Regí M, Colilla M, González B. Medical applications of organic–inorganic hybrid materials within the field of silica-based bioceramics. Chemical society reviews. 2011;40(2):596-607.

[31]. Zhao D, Feng J, Huo Q, Melosh N, Fredrickson GH, Chmelka BF, Stucky GD. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. science. 1998 Jan 23;279(5350):548-52.

[32]. Kankala RK, Han YH, Na J, Lee CH, Sun Z, Wang SB, Kimura T, Ok YS, Yamauchi Y, Chen AZ, Wu KC. Nanoarchitectured structure and surface biofunctionality of mesoporous silica nanoparticles. Advanced materials. 2020 Jun;32(23):1907035.

[33]. Slowing II, Trewyn BG, Giri S, Lin VY. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Advanced Functional Materials. 2007 May 21;17(8):1225-36.

[34]. Žid L, Zeleňák V, Almáši M, Zeleňáková A, Szücsová J, Bednarčík J, Šuleková M, Hudák A, Váhovská L. Mesoporous silica as a drug delivery system for naproxen: Influence of surface functionalization. Molecules. 2020 Jan;25(20):4722.

[35]. Diab R, Canilho N, Pavel IA, Haffner FB, Girardon M, Pasc A. Silica-based systems for oral delivery of drugs, macromolecules

and cells. Advances in Colloid and Interface Science. 2017 Nov 1;249:346-62.

[36]. Giorno L, Piacentini E, Bazzarelli F. Macroporous, Mesoporous, and Microporous Membranes. Encyclopedia of Membranes; Drioli, E., Giorno, L., Eds. 2016:1-2.

[37]. Garcia-Bennett AE. Synthesis, toxicology and potential of ordered mesoporous materials in nanomedicine. Nanomedicine. 2011 Jul;6(5):867-77.

[38]. Lee JE, Lee N, Kim T, Kim J, Hyeon T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Accounts of chemical research. 2011 Oct 18;44(10):893-902.

[39]. Liu J, Li C, Li F. Fluorescence turn-on chemodosimeter-functionalized mesoporous silica nanoparticles and their application in cell imaging. Journal of Materials Chemistry. 2011;21(20):7175-81.

[40]. Johnson BF. Nanoparticles in catalysis. Topics in Catalysis. 2003 Oct;24(1):147-59.

[41]. Popat A, Hartono SB, Stahr F, Liu J, Qiao SZ, Lu GQ. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers. Nanoscale. 2011;3(7):2801-18.

[42]. Popat A, Hartono SB, Stahr F, Liu J, Qiao SZ, Lu GQ. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers. Nanoscale. 2011;3(7):2801-18.

[43]. Salinas AJ, Esbrit P, Vallet-Regí M. A tissue engineering approach based on the use of bioceramics for bone repair. Biomaterials Science. 2013;1(1):40-51.

[44]. Ehlert N, Mueller PP, Stieve M, Lenarz T, Behrens P. Mesoporous silica films as a novel biomaterial: applications in the middle ear. Chemical Society Reviews. 2013;42(9):3847-61.

[45]. Vitale-Brovarone C, Baino F, Miola M, Mortera R, Onida B, Verné E. Glass–ceramic scaffolds containing silica mesophases for bone grafting and drug delivery. Journal of Materials Science: Materials in Medicine. 2009 Mar;20(3):809-20.

[46]. Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chemical Society Reviews. 2012;41(7):2590-605.

[47]. Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 2010 Sep 20;6(18):1952-67.

[48]. Yang P, Gai S, Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chemical Society Reviews. 2012;41(9):3679-98.

[49]. Wang Y, Yu A, Caruso F. Nanoporous polyelectrolyte spheres prepared by sequentially coating sacrificial mesoporous silica spheres. AngewandteChemie International Edition. 2005 May 6;44(19):2888-92.

[50]. Cui J, Yan Y, Wang Y, Caruso F. Templated assembly of pH-labile polymer-drug particles for intracellular drug delivery. Advanced Functional Materials. 2012 Nov 21;22(22):4718-23.

[51]. Trzeciak K, Chotera-Ouda A, Bak-Sypien II, Potrzebowski MJ. Mesoporous Silica Particles as Drug Delivery Systems—The State of the Art in Loading Methods and the Recent Progress in Analytical Techniques for Monitoring These Processes. Pharmaceutics. 2021 Jul;13(7):950.

[52]. Croissant JG, Fatieiev Y, Almalik A, Khashab NM. Mesoporous silica and organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applications. Advanced healthcare materials. 2018 Feb;7(4):1700831.

[53]. Narayan R, Nayak UY, Raichur AM, Garg S. Mesoporous silica nanoparticles: A comprehensive review on synthesis and recent advances. Pharmaceutics. 2018 Sep;10(3):118.

[54]. Yi Z, Dumée LF, Garvey CJ, Feng C, She F, Rookes JE, Mudie S, Cahill DM, Kong L. A new insight into growth mechanism and kinetics of mesoporous silica nanoparticles by in situ small angle X-ray scattering. Langmuir. 2015 Aug 4;31(30):8478-87.

[55]. Hollamby MJ, Borisova D, Brown P, Eastoe J, Grillo I, Shchukin D. Growth of mesoporous silica nanoparticles monitored

by time-resolved small-angle neutron scattering. Langmuir. 2012 Mar 6;28(9):4425-33.

[56]. Kresge AC, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. nature. 1992 Oct;359(6397):710-2.

[57]. Brinker CJ, Lu Y, Sellinger A, Fan H. Evaporation-induced self-assembly: nanostructures made easy. Advanced materials. 1999 May;11(7):579-85.

[58]. Karaman DŞ, Gulin-Sarfraz T, Zhang J, Rosenholm JM. One-pot synthesis of pore-expanded hollow mesoporous silica particles. Materials Letters. 2015 Mar 15;143:140-3.

[59]. Deekamwong K, Wittayakun J. Template removal by ion-exchange extraction from siliceous MCM-41 synthesized by microwave-assisted hydrothermal method. Microporous and Mesoporous Materials. 2017 Feb 1;239:54-9.

[60]. Bandyopadhyay M, Gies H. Synthesis of MCM-48 by microwave-hydrothermal process. ComptesRendusChimie. 2005 Mar 1;8(3-4):621-6.

[61]. Abdous B, Sajjadi SM, Ma'mani L. β-Cyclodextrin modified mesoporous silica nanoparticles as a nano-carrier: Response surface methodology to investigate and optimize loading and release processes for curcumin delivery. Journal of Applied Biomedicine. 2017 Jul 1;15(3):210-8.

[62]. Heikkilä T, Salonen J, Tuura J, Hamdy MS, Mul G, Kumar NA, Salmi T, Murzin DY, Laitinen L, Kaukonen AM, Hirvonen J. Mesoporous silica material TUD-1 as a drug delivery system. International journal of pharmaceutics. 2007 Feb 22;331(1):133-8.

[63]. Suriyanon N, Permrungruang J, Kaosaiphun J, Wongrueng A, Ngamcharussrivichai C, Punyapalakul P. Selective adsorption mechanisms of antilipidemic and non-steroidal anti-inflammatory drug residues on functionalized silica-based porous materials in a mixed solute. Chemosphere. 2015 Oct 1;136:222-31.

[64]. Kotcherlakota R, Barui AK, Prashar S, Fajardo M, Briones D, Rodríguez-Diéguez A, Patra CR, Gómez-Ruiz S. Curcumin loaded mesoporous silica: an effective drug delivery system for cancer treatment. Biomaterials science. 2016;4(3):448-59.

[65]. Lang Y, Finn DP, Pandit A, Walsh PJ. Pharmacological activity of ibuprofen released from mesoporous silica. Journal of Materials Science: Materials in Medicine. 2012 Jan;23(1):73-80.

[66]. Zeng W, Qian XF, Yin J, Zhu ZK. The drug delivery system of MCM-41 materials via co-condensation synthesis. Materials chemistry and physics. 2006 Jun 10;97(2-3):437-41.

[67]. Zhang LZ, Tang GQ, Gao BW, Zhang GL. Spectroscopic studies on the excited-state properties of the light-induced antiviral drug hypocrellin A loaded in the mesoporous solid. Chemical physics letters. 2004 Sep 21;396(1-3):102-9.

[68]. Deere J, Magner E, Wall JG, Hodnett BK. Adsorption and activity of proteins onto mesoporous silica. Catalysis Letters. 2003 Jan;85(1):19-23.

[69]. Miyahara M, Vinu A, Ariga K. Adsorption myoglobin over mesoporous silica molecular sieves: Pore size effect and pore-filling model. Materials science and Engineering: C. 2007 Mar 1;27(2):232-6.

[70]. Feng Y, Panwar N, Tng DJ, Tjin SC, Wang K, Yong KT. The application of mesoporous silica nanoparticle family in cancer theranostics. Coordination Chemistry Reviews. 2016 Jul 15;319:86-109.

[71]. Hamdy MS, Mul G, Jansen JC, Ebaid A, Shan Z, Overweg AR, Maschmeyer T. Synthesis, characterization, and unique catalytic performance of the mesoporous material Fe-TUD-1 in Friedel–Crafts benzylation of benzene. Catalysis today. 2005 Feb 28;100(3-4):255-60.

[72]. Kim TW, Kleitz F, Paul B, Ryoo R. MCM-48-like large mesoporous silicas with tailored pore structure: facile synthesis domain in a ternary triblock copolymer− butanol− water system. Journal of the American Chemical Society. 2005 May 25;127(20):7601-10.

[73]. Ma'Mani L, Nikzad S, Kheiri-Manjili H, Al-Musawi S, Saeedi M, Askarlou S, Foroumadi A, Shafiee A. Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for

the breast cancer therapy. European journal of medicinal chemistry. 2014 Aug 18;83:646-54.

[74]. Chen B, Quan G, Wang Z, Chen J, Wu L, Xu Y, Li G, Wu C. Hollow mesoporous silicas as a drug solution delivery system for insoluble drugs. Powder technology. 2013 May 1;240:48-53.

[75]. Liu J, Luo Z, Zhang J, Luo T, Zhou J, Zhao X, Cai K. Hollow mesoporous silica nanoparticles facilitated drug delivery via cascade pH stimuli in tumor microenvironment for tumor therapy. Biomaterials. 2016 Mar 1;83:51-65.

[76]. Butler KS, Durfee PN, Theron C, Ashley CE, Carnes EC, Brinker CJ. Protocells: modular mesoporous silica nanoparticle-supported lipid bilayers for drug delivery. small. 2016 Apr;12(16):2173-85.

[77]. Mornet S, Lambert O, Duguet E, Brisson A. The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. Nano letters. 2005 Feb 9;5(2):281-5.

[78]. Zhang J, Desai D, Rosenholm JM. Tethered lipid bilayer gates: toward extended retention of hydrophilic cargo in porous nanocarriers. Advanced Functional Materials. 2014 Apr;24(16):2352-60.

[79]. Desai D, Zhang J, Sandholm J, Lehtimäki J, Grönroos T, Tuomela J, Rosenholm JM. Lipid bilayer-gated mesoporous silica nanocarriers for tumor-targeted delivery of zoledronic acid in vivo. Molecular Pharmaceutics. 2017 Sep 5;14(9):3218-27.

[80]. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, Hanna TN, Liu J, Phillips B, Carter MB, Carroll NJ. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nature materials. 2011 May;10(5):389-97.

[81]. Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS nano. 2015 Apr 28;9(4):3540-57.

[82]. Cauda V, Engelke H, Sauer A, Arcizet D, Rädler J, Bein T. Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano letters. 2010 Jul 14;10(7):2484-92.

[83]. Wang LS, Wu LC, Lu SY, Chang LL, Teng IT, Yang CM, Ho JA. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS nano. 2010 Aug 24;4(8):4371-9.

[84]. Han N, Wang Y, Bai J, Liu J, Wang Y, Gao Y, Jiang T, Kang W, Wang S. Facile synthesis of the lipid bilayer coated mesoporous silica nanocomposites and their application in drug delivery. Microporous and mesoporous materials. 2016 Jan 1;219:209-18.

[85]. Huh S, Wiench JW, Yoo JC, Pruski M, Lin VS. Organic functionalization and morphology control of mesoporous silicas via a co-condensation synthesis method. Chemistry of materials. 2003 Nov 4;15(22):4247-56.

[86]. Wu SH, Hung Y, Mou CY. Mesoporous silica nanoparticles as nanocarriers. Chemical Communications. 2011;47(36):9972-85.

[87]. Andersson J, Rosenholm J, Areva S, Lindén M. Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro- and mesoporous silica matrices. Chemistry of Materials. 2004 Oct 19;16(21):4160-7.

[88]. Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert opinion on drug delivery. 2011 Oct 1;8(10):1361-78.

[89]. Prestidge CA, Barnes TJ, Lau CH, Barnett C, Loni A, Canham L. Mesoporous silicon: a platform for the delivery of therapeutics. Expert opinion on drug delivery. 2007 Mar 1;4(2):101-10.

[90]. Van Speybroeck M, Barillaro V, Do Thi T, Mellaerts R, Martens J, Van Humbeeck J, Vermant J, Annaert P, Van Den Mooter G, Augustijns P. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. Journal of pharmaceutical sciences. 2009 Aug 1;98(8):2648-58.

[91]. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. European journal of pharmaceutics and biopharmaceutics. 2004 May 1;57(3):533-40.

[92]. Ahern RJ, Hanrahan JP, Tobin JM, Ryan KB, Crean AM. Comparison of fenofibrate–mesoporous silica drug-loading processes for enhanced drug delivery. European Journal of Pharmaceutical Sciences. 2013 Nov 20;50(3-4):400-9.

[93]. McCarthy CA, Ahern RJ, Dontireddy R, Ryan KB, Crean AM. Mesoporous silica formulation strategies for drug dissolution enhancement: a review. Expert opinion on drug delivery. 2016 Jan 2;13(1):93-108.

[94]. Skorupska E, Jeziorna A, Paluch P, Potrzebowski MJ. Ibuprofen in mesopores of mobil crystalline material 41 (MCM-41): a deeper understanding. Molecular Pharmaceutics. 2014 May 5;11(5):1512-9.

[95]. Mellaerts R, Jammaer JA, Van Speybroeck M, Chen H, Humbeeck JV, Augustijns P, Van den Mooter G, Martens JA. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir. 2008 Aug 19;24(16):8651-9.

[96]. Heikkilä T, Salonen J, Tuura J, Hamdy MS, Mul G, Kumar NA, Salmi T, Murzin DY, Laitinen L, Kaukonen AM, Hirvonen J. Mesoporous silica material TUD-1 as a drug delivery system. International journal of pharmaceutics. 2007 Feb 22;331(1):133-8.

[97]. Qu F, Zhu G, Lin H, Zhang W, Sun J, Li S, Qiu S. A controlled release of ibuprofen by systematically tailoring the morphology of mesoporous silica materials. Journal of Solid State Chemistry. 2006 Jul 1;179(7):2027-35.

[98]. Ambrogi V, Perioli L, Pagano C, Latterini L, Marmottini F, Ricci M, Rossi C. MCM-41 for furosemide dissolution improvement. Microporous and mesoporous materials. 2012 Jan 1;147(1):343-9.

[99]. Qian KK, Bogner RH. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. Journal of pharmaceutical sciences. 2012 Feb 1;101(2):444-63.

[100]. Guideline IH. Assessment and control of dna reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7. InInternational conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH): Geneva 2014 Jun 5.

[101]. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. European journal of pharmaceutics and biopharmaceutics. 2004 May 1;57(3):533-40.

[102]. Brás AR , Fonseca IM , Dionísio M , Schönhals A , Affouard F, Correia NT. Influence of nanoscale confinement on the molecular mobility of ibuprofen. The Journal of Physical Chemistry C. 2014 Jun 26;118(25):13857-68.

[103]. Shen J, He Q, Gao Y, Shi J, Li Y. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. Nanoscale. 2011;3(10):4314-22.

[104]. Xie X, Li F, Zhang H, Lu Y, Lian S, Lin H, Gao Y, Jia L. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. European Journal of Pharmaceutical Sciences. 2016 Feb 15;83:28-35.

[105]. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. European journal of pharmaceutics and biopharmaceutics. 2004 May 1;57(3):533-40.

[106]. Van Speybroeck M, Mellaerts R, Mols R, Do Thi T, Martens JA, Van Humbeeck J, Annaert P, Van den Mooter G, Augustijns P. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. European Journal of Pharmaceutical Sciences. 2010 Dec 23;41(5):623-30.

[107]. Ahern RJ, Crean AM, Ryan KB. The influence of supercritical carbon dioxide (SC-CO2) processing conditions on drug loading and physicochemical properties.

International journal of pharmaceutics. 2012 Dec 15;439(1-2):92-9.

[108]. Bouledjouidja A, Masmoudi Y, Van Speybroeck M, Schueller L, Badens E. Impregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxide. International Journal of Pharmaceutics. 2016 Feb 29;499(1-2):1-9.

[109]. Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2001;18(2).

[110]. Pasquali I, Bettini R. Are pharmaceutics really going supercritical?. International journal of pharmaceutics. 2008 Dec 8;364(2):176-87.

[111]. Gignone A, Manna L, Ronchetti S, Banchero M, Onida B. Incorporation of clotrimazole in Ordered Mesoporous Silica by supercritical CO2. Microporous and mesoporous materials. 2014 Dec 1;200:291-6.

[112]. Bush JR, Akgerman A, Hall KR. Synthesis of controlled release device with supercritical CO2 and co-solvent. The Journal of supercritical fluids. 2007 Jun 1;41(2):311-6.

[113]. Zhang Z, Quan G, Wu Q, Zhou C, Li F, Bai X, Li G, Pan X, Wu C. Loading amorphous Asarone in mesoporous silica SBA-15 through supercritical carbon dioxide technology to enhance dissolution and bioavailability. European Journal of Pharmaceutics and Biopharmaceutics. 2015 May 1;92:28-31.

[114]. Guan J, Han J, Zhang D, Chu C, Liu H, Sun J, He Z, Zhang T. Increased dissolution rate and oral bioavailability of hydrophobic drug glyburide tablets produced using supercritical CO2 silica dispersion technology. European Journal of Pharmaceutics and Biopharmaceutics. 2014 Apr 1;86(3):376-82.

[115]. Li-Hong W, Xin C, Hui X, Li-Li Z, Jing H, Mei-Juan Z, Jie L, Yi L, Jin-Wen L, Wei Z, Gang C. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique. International journal of pharmaceutics. 2013 Sep 15;454(1):135-42.

[116]. Gurikov P, Smirnova I. Amorphization of drugs by adsorptive precipitation from supercritical solutions: A review. The Journal of Supercritical Fluids. 2018 Feb 1;132:105-25.

[117]. Padrela L, Rodrigues MA, Duarte A, Dias AM, Braga ME, de Sousa HC. Supercritical carbon dioxide-based technologies for the production of drug nanoparticles/nanocrystals–a comprehensive review. Advanced drug delivery reviews. 2018 Jun 1;131:22-78.

[118]. Dement'Eva OV, Senchikhin IN, Kartseva ME, Ogarev VA, Zaitseva AV, Matushkina NN, Rudoy VM. A new method for loading mesoporous silica nanoparticles with drugs: Sol–gel synthesis using drug micelles as a template. Colloid Journal. 2016 Sep;78(5):586-95.

[119]. Dohrn R, Bertakis E, Behrend O, Voutsas E, Tassios D. Melting point depression by using supercritical CO2 for a novel melt dispersion micronization process. Journal of Molecular Liquids. 2007 Mar 15;131:53-9.

[120]. Chen B, Quan G, Wang Z, Chen J, Wu L, Xu Y, Li G, Wu C. Hollow mesoporous silicas as a drug solution delivery system for insoluble drugs. Powder technology. 2013 May 1;240:48-53.

[121]. Wang Y, Sun L, Jiang T, Zhang J, Zhang C, Sun C, Deng Y, Sun J, Wang S. The investigation of MCM-48-type and MCM-41-type mesoporous silica as oral solid dispersion carriers for water insoluble cilostazol. Drug development and industrial pharmacy. 2014 Jun 1;40(6):819-28.

[122]. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, Hanna TN, Liu J, Phillips B, Carter MB, Carroll NJ. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nature materials. 2011 May;10(5):389-97.

[123]. Epler K, Padilla D, Phillips G, Crowder P, Castillo R, Wilkinson D, Wilkinson B, Burgard C, Kalinich R, Townson J, Chackerian B. Delivery of ricin toxin a-chain by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. Advanced healthcare materials. 2012 May;1(3):348-53.

[124]. Ashley CE, Carnes EC, Epler KE, Padilla DP, Phillips GK, Castillo RE, Wilkinson DC, Wilkinson BS, Burgard CA, Kalinich RM, Townson JL. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS nano. 2012 Mar 27;6(3):2174-88.

[125]. Limnell T, Santos HA, Mäkilä E, Heikkilä T, Salonen J, Murzin DY, Kumar N, Laaksonen T, Peltonen L, Hirvonen J. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods. Journal of pharmaceutical sciences. 2011 Aug 1;100(8):3294-306.

[126]. Shen SC, Ng WK, Chia L, Dong YC, Tan RB. Stabilized amorphous state of ibuprofen by co-spray drying with mesoporous SBA-15 to enhance dissolution properties. Journal of pharmaceutical sciences. 2010 Apr 1;99(4):1997-2007.

[127]. Hong S, Shen S, Tan DC, Ng WK, Liu X, Chia LS, Irwan AW, Tan R, Nowak SA, Marsh K, Gokhale R. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods. Drug delivery. 2016 Jan 2;23(1):316-27.

[128]. Bahl D, Hudak J, Bogner RH. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharmaceutical development and technology. 2008 Jan 1;13(3):255-69.

[129]. Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. European journal of pharmaceutics and biopharmaceutics. 2004 May 1;57(3):533-40.

[130]. Heikkilä T, Salonen J, Tuura J, Kumar N, Salmi T, Murzin DY, Hamdy MS, Mul G, Laitinen L, Kaukonen AM, Hirvonen J. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug delivery. 2007 Jan 1;14(6):337-47.

[131]. Izquierdo-Barba I, Martinez Á, Doadrio AL, Pérez-Pariente J, Vallet-Regí M. Release evaluation of drugs from ordered three-dimensional silica structures. European Journal of Pharmaceutical Sciences. 2005 Dec 1;26(5):365-73.

[132]. Aerts CA, Verraedt E, Mellaerts R, Depla A, Augustijns P, Van Humbeeck J, Van den Mooter G, Martens JA. Tunability of pore diameter and particle size of amorphous microporous silica for diffusive controlled release of drug compounds. The Journal of Physical Chemistry C. 2007 Sep 13;111(36):13404-9.

[133]. Horcajada P, Ramila A, Perez-Pariente J, Vallet-Regı M. Influence of pore size of MCM-41 matrices on drug delivery rate. Microporous and Mesoporous Materials. 2004 Mar 8;68(1-3):105-9.

[134]. Tozuka Y, Wongmekiat A, Kimura K, Moribe K, Yamamura S, Yamamoto K. Effect of pore size of FSM-16 on the entrapment of flurbiprofen in mesoporous structures. Chemical and pharmaceutical bulletin. 2005;53(8):974-7.

[135]. Ukmar T, Maver U, Planinšek O, Kaučič V, Gaberščck M, Godec A. Understanding controlled drug release from mesoporous silicates: theory and experiment. Journal of controlled release. 2011 Nov 7;155(3):409-17.

[136]. Gao L, Sun J, Zhang L, Wang J, Ren B. Influence of different structured channels of mesoporous silicate on the controlled ibuprofen delivery. Materials Chemistry and Physics. 2012 Aug 15;135(2-3):786-97.

[137]. Zhu YF, Shi JL, Li YS, Chen HR, Shen WH, Dong XP. Hollow mesoporous spheres with cubic pore network as a potential carrier for drug storage and its in vitro release kinetics. Journal of materials research. 2005 Jan;20(1):54-61.

[138]. Zhang Y, Zhi Z, Jiang T, Zhang J, Wang Z, Wang S. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. Journal of Controlled Release. 2010 Aug 3;145(3):257-63.

[139]. Mellaerts R, Houthoofd K, Elen K, Chen H, Van Speybroeck M, Van Humbeeck J, Augustijns P, Mullens J, Van den Mooter G, Martens JA. Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material.

Microporous and Mesoporous Materials. 2010 May 1;130(1-3):154-61.

[140]. Sliwinska-Bartkowiak M, Dudziak G, Gras R, Sikorski R, Radhakrishnan R, Gubbins KE. Freezing behavior in porous glasses and MCM-41. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2001 Aug 31;187:523-9.

[141]. Rengarajan GT, Enke D, Steinhart M, Beiner M. Stabilization of the amorphous state of pharmaceuticals in nanopores. Journal of Materials Chemistry. 2008;18(22):2537-9.

[142]. Jia L, Shen J, Li Z, Zhang D, Zhang Q, Duan C, Liu G, Zheng D, Liu Y, Tian X. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs. International journal of pharmaceutics. 2012 Dec 15;439(1-2):81-91.

[143]. Shen SC, Ng WK, Chia L, Hu J, Tan RB. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. International journal of pharmaceutics. 2011 May 30;410(1-2):188-95.

[144]. Hu Y, Wang J, Zhi Z, Jiang T, Wang S. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. Journal of colloid and interface science. 2011 Nov 1;363(1):410-7.

[145]. Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. International journal of pharmaceutics. 2013 Aug 30;453(1):181-97.

[146]. Kresge AC, Leonowicz ME, Roth WJ, Vartuli JC, Beck JS. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. nature. 1992 Oct;359(6397):710-2.

[147]. Zhao D, Feng J, Huo Q, Melosh N, Fredrickson GH, Chmelka BF, Stucky GD. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. science. 1998 Jan 23;279(5350):548-52.

[148]. Mellaerts R, Aerts CA, Van Humbeeck J, Augustijns P, Van den Mooter G, Martens JA. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chemical Communications. 2007(13):1375-7.

[149]. Miura H, Kanebako M, Shirai H, Nakao H, Inagi T, Terada K. Stability of amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio) phenyl]-2H-pyridazin-3-one, in silica mesopores and measurement of its molecular mobility by solid-state 13C NMR spectroscopy. International journal of pharmaceutics. 2011 May 30;410(1-2):61-7.

[150]. Gao L, Sun J, Zhang L, Wang J, Ren B. Influence of different structured channels of mesoporous silicate on the controlled ibuprofen delivery. Materials Chemistry and Physics. 2012 Aug 15;135(2-3):786-97.

[151]. Qi L, Ma J, Cheng H, Zhao Z. Micrometer-sized mesoporous silica spheres grown under static conditions. Chemistry of materials. 1998 Jun 15;10(6):1623-6.

[152]. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Advanced drug delivery reviews. 2008 Aug 17;60(11):1278-88.

[153]. Qu F, Zhu G, Huang S, Li S, Sun J, Zhang D, Qiu S. Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica. Microporous and Mesoporous Materials. 2006 Jun 20;92(1-3):1-9.

[154]. Manzano M, Aina V, Arean CO, Balas F, Cauda V, Colilla M, Delgado MR, Vallet-Regi M. Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalization. Chemical Engineering Journal. 2008 Mar 15;137(1):30-7.

[155]. Hu J, Rogers TL, Brown J, Young T, Johnston KP, Williams Iii RO. Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. Pharmaceutical research. 2002 Sep;19(9):1278-84.

[156]. Friedrich H, Fussnegger B, Kolter K, Bodmeier R. Dissolution rate improvement of poorly water-soluble

drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. European journal of pharmaceutics and biopharmaceutics. 2006 Feb 1;62(2):171-7.

[157]. Horcajada P, Ramila A, Perez-Pariente J, Vallet-Regı M. Influence of pore size of MCM-41 matrices on drug delivery rate. Microporous and Mesoporous Materials. 2004 Mar 8;68(1-3):105-9.

[158]. Kumar D, Chirravuri SS, Shastri NR. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: A case study with aceclofenac. International Journal of Pharmaceutics. 2014 Jan 30;461(1-2):459-68.

[159]. Song SW, Hidajat K, Kawi S. Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix− drug interactions. Langmuir. 2005 Oct 11;21(21):9568-75.

[160]. Balas F, Manzano M, Horcajada P, Vallet-Regí M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. Journal of the American Chemical Society. 2006 Jun 28;128(25):8116-7.

[161]. Doadrio JC, Sousa EM, Izquierdo-Barba I, Doadrio AL, Perez-Pariente J, Vallet-Regí M. Functionalization of mesoporous materials with long alkyl chains as a strategy for controlling drug delivery pattern. Journal of Materials Chemistry. 2006;16(5):462-6.

[162]. Qu F, Zhu G, Huang S, Li S, Qiu S. Effective controlled release of captopril by silylation of mesoporous MCM-41. Chemphyschem: a European journal of chemical physics and physical chemistry. 2006 Feb 13;7(2):400-6.

[163]. Tang Q, Xu Y, Wu D, Sun Y, Wang J, Xu J, Deng F. Studies on a new carrier of trimethylsilyl-modified mesoporous material for controlled drug delivery. Journal of Controlled Release. 2006 Aug 10;114(1):41-6.

[164]. Fu C, Liu T, Li L, Liu H, Chen D, Tang F. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013 Mar 1;34(10):2565-75.

[165]. Awaad A, Nakamura M, Ishimura K. Imaging of size-dependent uptake and identification of novel pathways in mouse Peyer's patches using fluorescent organosilica particles. Nanomedicine: Nanotechnology, Biology and Medicine. 2012 Jul 1;8(5):627-36.

[166]. Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: the phagocyte problem. Nano today. 2015 Aug 1;10(4):487-510.

[167]. Ishak RA, Awad GA, Zaki NM, El-Shamy AE, Mortada ND. A comparative study of chitosan shielding effect on nano-carriers hydrophilicity and biodistribution. Carbohydrate polymers. 2013 Apr 15;94(1):669-76.

[168]. Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. Folate-targeted nanoparticles for rheumatoid arthritis therapy. Nanomedicine: Nanotechnology, Biology and Medicine. 2016 May 1;12(4):1113-26.

[169]. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced drug delivery reviews. 2016 Apr 1;99:28-51.

[170]. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. Journal of Materials Chemistry. 2011;21(16):5845-55.

[171]. Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies NM. Clinical toxicities of nanocarrier systems. Advanced drug delivery reviews. 2008 May 22;60(8):929-38.

[172]. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010 Aug 16;6(16):1794-805.

[173]. Li L, Liu T, Fu C, Tan L, Meng X, Liu H. Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape. Nanomedicine: Nanotechnology, Biology and Medicine. 2015 Nov 1;11(8):1915-24.

[174]. Croissant JG, Fatieiev Y, Khashab NM. Degradability and clearance of silicon,

organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Advanced materials. 2017 Mar;29(9):1604634.

[175]. Ma'Mani L, Nikzad S, Kheiri-Manjili H, Al-Musawi S, Saeedi M, Askarlou S, Foroumadi A, Shafiee A. Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy. European journal of medicinal chemistry. 2014 Aug 18;83:646-54.

[176]. Xie X, Li F, Zhang H, Lu Y, Lian S, Lin H, Gao Y, Jia L. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. European Journal of Pharmaceutical Sciences. 2016 Feb 15;83:28-35.

[177]. Varache M, Bezverkhyy I, Saviot L, Bouyer F, Baras F, Bouyer F. Optimization of MCM-41 type silica nanoparticles for biological applications: Control of size and absence of aggregation and cell cytotoxicity. Journal of Non-Crystalline Solids. 2015 Jan 15;408:87-97.

[178]. Li J, Du X, Zheng N, Xu L, Xu J, Li S. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity. Colloids and Surfaces B: Biointerfaces. 2016 May 1;141:374-81.

[179]. Biswas N. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan. European Journal of Pharmaceutical Sciences. 2017 Mar 1;99:152-60.

[180]. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. Journal of Materials Chemistry. 2011;21(16):5845-55.

[181]. Sergent JA, Paget V, Chevillard S. Toxicity and genotoxicity of nano-SiO2 on human epithelial intestinal HT-29 cell line. Annals of occupational hygiene. 2012 Jul 1;56(5):622-30.

[182]. Zhang Q, Xu H, Zheng S, Su M, Wang J. Genotoxicity of mesoporous silica nanoparticles in human embryonic kidney 293 cells. Drug testing and analysis. 2015 Sep;7(9):787-96.

[183]. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. small. 2007 Aug 3;3(8):1341-6.

[184]. Gunduz O, Yetmez M, Sonmez M, Georgescu M, Alexandrescu L, Ficai A, Ficai D, Andronescu E. Mesoporous materials used in medicine and environmental applications. Current topics in medicinal chemistry. 2015 Aug 1;15(15):1501-15.

[185]. Wu SH, Hung Y, Mou CY. Mesoporous silica nanoparticles as nanocarriers. Chemical Communications. 2011;47(36):9972-85.

[186]. Chen X, Zhouhua W, Jie Z, Xinlu F, Jinqiang L, Yuwen Q, Zhiying H. Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway. International journal of nanomedicine. 2015;10:1.

[187]. Yildirim A, Ozgur E, Bayindir M. Impact of mesoporous silica nanoparticle surface functionality on hemolytic activity, thrombogenicity and non-specific protein adsorption. Journal of Materials Chemistry B. 2013;1(14):1909-20.

[188]. Lin CH, Cheng SH, Liao WN, Wei PR, Sung PJ, Weng CF, Lee CH. Mesoporous silica nanoparticles for the improved anticancer efficacy of cis-platin. International journal of pharmaceutics. 2012 Jun 15;429(1-2):138-47.

[189]. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010 Aug 16;6(16):1794-805.

[190]. Yu T, Greish K, McGill LD, Ray A, Ghandehari H. Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS nano. 2012 Mar 27;6(3):2289-301.

[191]. Shi Y, Miller ML, Di Pasqua AJ. Biocompatibility of mesoporous silica nanoparticles?. Comments on Inorganic Chemistry. 2016 Mar 3;36(2):61-80.

[192]. Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. International journal of pharmaceutics. 2013 Aug 30;453(1):181-97.

[193]. Thomas MJ, Slipper I, Walunj A, Jain A, Favretto ME, Kallinteri P, Douroumis D. Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. international Journal of Pharmaceutics. 2010 Mar 15;387(1-2):272-7.

[194]. Summerlin N, Qu Z, Pujara N, Sheng Y, Jambhrunkar S, McGuckin M, Popat A. Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol. Colloids and Surfaces B: Biointerfaces. 2016 Aug 1;144:1-7.

[195]. Bukara K, Schueller L, Rosier J, Martens MA, Daems T, Verheyden L, Eelen S, Van Speybroeck M, Libanati C, Martens JA, Van Den Mooter G. Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man. European Journal of Pharmaceutics and Biopharmaceutics. 2016 Nov 1;108:220-5.

[196]. Jia L, Shen J, Li Z, Zhang D, Zhang Q, Duan C, Liu G, Zheng D, Liu Y, Tian X. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs. International journal of pharmaceutics. 2012 Dec 15;439(1-2):81-91.

[197]. He D, He X, Wang K, Cao J, Zhao Y. A light-responsive reversible molecule-gated system using thymine-modified mesoporous silica nanoparticles. Langmuir. 2012 Feb 28;28(8):4003-8.

[198]. Knežević NŽ, Trewyn BG, Lin VS. Functionalized mesoporous silica nanoparticle-based visible light responsive controlled release delivery system. Chemical Communications. 2011;47(10):2817-9.

[199]. Croissant J, Maynadier M, Gallud A, PeindyN'Dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N. Two-Photon-Triggered Drug Delivery in Cancer Cells Using Nanoimpellers. AngewandteChemie. 2013 Dec 16;125(51):14058-62.

[200]. Zhang Z, Wang L, Wang J, Jiang X, Li X, Hu Z, Ji Y, Wu X, Chen C. Mesoporous silica-coated gold nanorods as a light-mediated multifunctional theranostic platform for cancer treatment. Advanced materials. 2012 Mar 15;24(11):1418-23.

[201]. Liu J, Bu W, Pan L, Shi J. NIR-triggered anticancer drug delivery by upconverting nanoparticles with integrated azobenzene-modified mesoporous silica. AngewandteChemie. 2013 Apr 15;125(16):4471-5.

[202]. Croissant J, Zink JI. Nanovalve-controlled cargo release activated by plasmonic heating. Journal of the American Chemical Society. 2012 May 9;134(18):7628-31.

[203]. Saint-Cricq P, Deshayes S, Zink JI, Kasko AM. Magnetic field activated drug delivery using thermodegradable azo-functionalised PEG-coated core–shell mesoporous silica nanoparticles. Nanoscale. 2015;7(31):13168-72.

[204]. Ruiz-Hernandez E, Baeza A, Vallet-Regi M. Smart drug delivery through DNA/magnetic nanoparticle gates. ACS nano. 2011 Feb 22;5(2):1259-66.

[205]. Thomas CR, Ferris DP, Lee JH, Choi E, Cho MH, Kim ES, Stoddart JF, Shin JS, Cheon J, Zink JI. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. Journal of the American Chemical Society. 2010 Aug 11;132(31):10623-5.

[206]. Karimi M, Mirshekari H, Aliakbari M, Sahandi-Zangabad P, Hamblin MR. Smart mesoporous silica nanoparticles for controlled-release drug delivery. Nanotechnology Reviews. 2016 Apr 1;5(2):195-207.

[207]. Lin JT, Liu ZK, Zhu QL, Rong XH, Liang CL, Wang J, Ma D, Sun J, Wang GH. Redox-responsive nanocarriers for drug and gene co-delivery based on chitosan derivatives modified mesoporous silica nanoparticles. Colloids and Surfaces B: Biointerfaces. 2017 Jul 1;155:41-50.

[208]. Moreira AF, Dias DR, Correia IJ. Stimuli-responsive mesoporous silica nanoparticles for cancer therapy: A review. Microporous and Mesoporous Materials. 2016 Dec 1;236:141-57.

[209]. Yang KN, Zhang CQ, Wang W, Wang PC, Zhou JP, Liang XJ. pH-responsive

mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment. Cancer biology & medicine. 2014 Mar;11(1):34.

[210]. Ambrogio MW, Pecorelli TA, Patel K, Khashab NM, Trabolsi A, Khatib HA, Botros YY, Zink JI, Stoddart JF. Snap-top nanocarriers. Organic Letters. 2010 Aug 6;12(15):3304-7.

[211]. Luo Z, Cai K, Hu Y, Zhao L, Liu P, Duan L, Yang W. Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. AngewandteChemie. 2011 Jan 17;123(3):666-9.

[212]. Chen X, Sun H, Hu J, Han X, Liu H, Hu Y. Transferrin gated mesoporous silica nanoparticles for redox-responsive and targeted drug delivery. Colloids and Surfaces B: Biointerfaces. 2017 Apr 1;152:77-84.

[213]. He Q, Gao Y, Zhang L, Zhang Z, Gao F, Ji X, Li Y, Shi J. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials. 2011 Oct 1;32(30):7711-20.

[214]. Zhu Y, Shi J, Shen W, Dong X, Feng J, Ruan M, Li Y. Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere/polyelectrolyte multilayer core–shell structure. AngewandteChemie. 2005 Aug 12;117(32):5213-7.

[215]. Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. Journal of the American Chemical Society. 2010 Sep 15;132(36):12690-7.

[216]. Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, AlMalik AM, Zink JI, Khashab NM. Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. Journal of Controlled Release. 2016 May 10;229:183-91.

[217]. Cheng W, Nie J, Xu L, Liang C, Peng Y, Liu G, Wang T, Mei L, Huang L, Zeng X. pH-sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted cancer therapy. ACS applied materials & interfaces. 2017 Jun 7;9(22):18462-73.

[218]. Nadrah P, Planinšek O, Gaberšček M. Stimulus-responsive mesoporous silica particles. Journal of Materials Science. 2014 Jan;49(2):481-95.

[219]. Li X, Tang T, Zhou Y, Zhang Y, Sun Y. Applicability of enzyme-responsive mesoporous silica supports capped with bridged silsesquioxane for colon-specific drug delivery. Microporous and mesoporous materials. 2014 Jan 15;184:83-9.

[220]. Chen X, Liu Z. Dual responsive mesoporous silica nanoparticles for targeted co-delivery of hydrophobic and hydrophilic anticancer drugs to tumor cells. Journal of Materials Chemistry B. 2016;4(25):4382-8.

[221]. Tian Z, Yu X, Ruan Z, Zhu M, Zhu Y, Hanagata N. Magnetic mesoporous silica nanoparticles coated with thermo-responsive copolymer for potential chemo-and magnetic hyperthermia therapy. Microporous and Mesoporous Materials. 2018 Jan 15;256:1-9.

[222]. Wen J, Yang K, Xu Y, Li H, Liu F, Sun S. Construction of a triple-stimuli-responsive system based on cerium oxide coated mesoporous silica nanoparticles. Scientific reports. 2016 Dec 12;6(1):1-0.

[223]. Tarn D, Ashley CE, Xue MI, Carnes EC, Zink JI, Brinker CJ. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Accounts of chemical research. 2013 Mar 19;46(3):792-801.

[224]. Yang Y, Yu C. Advances in silica based nanoparticles for targeted cancer therapy. Nanomedicine: Nanotechnology, Biology and Medicine. 2016 Feb 1;12(2):317-32.

[225]. Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells. Nanoscale. 2013;5(1):178-83.

[226]. Sarkar A, Ghosh S, Chowdhury S, Pandey B, Sil PC. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells. Biochimica et

Biophysica Acta (BBA)-General Subjects. 2016 Oct 1;1860(10):2065-75.

[227]. Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chemical Society Reviews. 2012;41(7):2590-605.

[228]. Li X, Wu M, Pan L, Shi J. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor. International journal of nanomedicine. 2016;11:93.

[229]. Pan L, He Q, Liu J, Chen Y, Ma M, Zhang L, Shi J. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. Journal of the American Chemical Society. 2012 Apr 4;134(13):5722-5.

[230]. Pan L, Shi J. Chemical Design of Nuclear-Targeting Mesoporous Silica Nanoparticles for Intra-nuclear Drug Delivery. Chinese Journal of Chemistry. 2018 Jun;36(6):481-6.

[231]. Xiong L, Du X, Kleitz F, Qiao SZ. Cancer-cell-specific nuclear-targeted drug delivery by dual-ligand-modified mesoporous silica nanoparticles. Small. 2015 Nov;11(44):5919-26.

[232]. Duo Y, Yang M, Du Z, Feng C, Xing C, Wu Y, Xie Z, Zhang F, Huang L, Zeng X, Chen H. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy. Acta Biomaterialia. 2018 Oct 1;79:317-30.

[233]. Qu Q, Ma X, Zhao Y. Targeted delivery of doxorubicin to mitochondria using mesoporous silica nanoparticle nanocarriers. Nanoscale. 2015;7(40):16677-86.

[234]. Chen WH, Luo GF, Lei Q, Cao FY, Fan JX, Qiu WX, Jia HZ, Hong S, Fang F, Zeng X, Zhuo RX. Rational design of multifunctional magnetic mesoporous silica nanoparticle for tumor-targeted magnetic resonance imaging and precise therapy. Biomaterials. 2016 Jan 1;76:87-101.

[235]. Liu J, Liu T, Pan J, Liu S, Lu GQ. Advances in multicompartment mesoporous silica micro/nanoparticles for theranostic applications. Annual Review of Chemical and Biomolecular Engineering. 2018 Jun 7;9:389-411.

[236]. Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, Che E, Hu L, Zhang Q, Jiang T, Wang S. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine: Nanotechnology, Biology and Medicine. 2015 Feb 1;11(2):313-27.

[237]. Huang G, Liu R, Hu Y, Li SH, Wu Y, Qiu Y, Li J, Yang HH. FeOOH-loaded mesoporous silica nanoparticles as a theranostic platform with pH-responsive MRI contrast enhancement and drug release. Science China Chemistry. 2018 Jul;61(7):806-11.

[238]. Chen Y, Ai K, Liu J, Sun G, Yin Q, Lu L. Multifunctional envelope-type mesoporous silica nanoparticles for pH-responsive drug delivery and magnetic resonance imaging. Biomaterials. 2015 Aug 1;60:111-20.

[239]. Lee CH, Cheng SH, Wang YJ, Chen YC, Chen NT, Souris J, Chen CT, Mou CY, Yang CS, Lo LW. Near-infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution. Advanced Functional Materials. 2009 Jan 23;19(2):215-22.

[240]. Portilho FL, Helal-Neto E, Cabezas SS, Pinto SR, Dos Santos SN, Pozzo L, Sancenon F, Martinez-Manez R, Santos-Oliveira R. Magnetic core mesoporous silica nanoparticles doped with dacarbazine and labelled with 99mTc for early and differential detection of metastatic melanoma by single photon emission computed tomography. Artificial Cells, Nanomedicine, and Biotechnology. 2018 Oct 31;46(sup1):1080-7.